Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P11802
UPID:
CDK4_HUMAN
Alternative names:
Cell division protein kinase 4; PSK-J3
Alternative UPACC:
P11802; B2R9A0; B4DNF9; O00576; Q6FG61
Background:
Cyclin-dependent kinase 4 (CDK4), also known as Cell division protein kinase 4 and PSK-J3, plays a pivotal role in cell cycle regulation. As a Ser/Thr-kinase component of cyclin D-CDK4 complexes, it phosphorylates and inhibits members of the retinoblastoma (RB) protein family, facilitating G(1)/S transition in the cell cycle. This process involves the phosphorylation of RB1, enabling the transcription of E2F target genes crucial for cell cycle progression.
Therapeutic significance:
CDK4's involvement in melanoma, cutaneous malignant 3, underscores its therapeutic significance. Disease susceptibility is linked to genetic variants affecting CDK4, highlighting its potential as a target for therapeutic intervention in melanoma treatment. Understanding the role of Cyclin-dependent kinase 4 could open doors to potential therapeutic strategies.